Geode Capital Management LLC Trims Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Geode Capital Management LLC decreased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 0.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,000,868 shares of the company's stock after selling 7,346 shares during the period. Geode Capital Management LLC owned approximately 1.17% of CRISPR Therapeutics worth $39,412,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. ARK Investment Management LLC increased its holdings in shares of CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock worth $353,180,000 after buying an additional 1,474,439 shares during the last quarter. Norges Bank purchased a new stake in CRISPR Therapeutics during the fourth quarter valued at approximately $17,458,000. Contrarius Group Holdings Ltd bought a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at approximately $14,516,000. Raymond James Financial Inc. purchased a new position in shares of CRISPR Therapeutics in the 4th quarter worth approximately $3,231,000. Finally, Van ECK Associates Corp increased its position in shares of CRISPR Therapeutics by 5,269.3% during the 4th quarter. Van ECK Associates Corp now owns 83,010 shares of the company's stock valued at $3,267,000 after purchasing an additional 81,464 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Stock Down 0.0 %

NASDAQ CRSP traded down $0.01 during trading on Friday, hitting $37.77. The stock had a trading volume of 1,027,190 shares, compared to its average volume of 1,631,291. The firm has a 50 day moving average price of $40.93 and a 200 day moving average price of $43.74. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $67.88. The company has a market capitalization of $3.24 billion, a PE ratio of -8.64 and a beta of 1.85.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on CRSP. Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, February 12th. Royal Bank of Canada cut their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a report on Wednesday, February 12th. Citigroup decreased their price objective on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a research note on Tuesday, February 18th. Needham & Company LLC reiterated a "buy" rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, April 9th. Finally, Cantor Fitzgerald restated a "neutral" rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $73.11.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, COO Julianne Bruno sold 1,198 shares of the firm's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the sale, the chief operating officer now directly owns 8,263 shares in the company, valued at $350,516.46. This trade represents a 12.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of the company's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,381 shares of company stock valued at $1,608,243 in the last quarter. Corporate insiders own 4.10% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.